Phase II trial of gemcitabine and nab‐paclitaxel in patients with recurrent Ewing sarcoma: A report from the National Pediatric Cancer Foundation

Management of recurrent Ewing sarcoma: challenges and approaches

(2019) David Van Mater et al.   OncoTargets and Therapy

Phase I results of a phase I/II study of weekly nab -paclitaxel in paediatric patients with recurrent/refractory solid tumours: A collaboration with innovative therapies for children with cancer

(2018) Lucas Moreno et al.   EUROPEAN JOURNAL OF CANCER

Gemcitabine/nab-paclitaxel for pediatric relapsed/refractory sarcomas

(2018) Jonathan L. Metts et al.   PEDIATRIC BLOOD & CANCER

Caveolin-1 expression predicts efficacy of weekly nab-paclitaxel plus gemcitabine for metastatic breast cancer in the phase II clinical trial

(2018) Yannan Zhao et al.   BMC CANCER

Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial

(2017) Beatrice Seddon et al.   LANCET ONCOLOGY

Efficacy and safety of gemcitabine plus docetaxel in Japanese patients with unresectable or recurrent bone and soft tissue sarcoma: Results from a single-institutional analysis

(2017) Masanobu Takahashi et al.   PLoS One

Feasibility and efficacy of gemcitabine and docetaxel combination chemotherapy for bone and soft tissue sarcomas: multi-institutional retrospective analysis of 134 patients

(2016) Kazuhiro Tanaka et al.   World Journal of Surgical Oncology

SPARC is a possible predictive marker for albumin-bound paclitaxel in non-small-cell lung cancer

(2016) Kazutoshi Komiya et al.   OncoTargets and Therapy

SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial

(2015) M. Hidalgo et al.   CLINICAL CANCER RESEARCH

Stromal Caveolin-1 Is Associated With Response and Survival in a Phase II Trial of nab-Paclitaxel With Carboplatin for Advanced NSCLC Patients

(2015) Erin M. Bertino et al.   Clinical Lung Cancer

Initial testing (stage 1) of the tubulin binding agent nanoparticle albumin-bound (nab) paclitaxel (Abraxane®) by the Pediatric Preclinical Testing Program (PPTP)

(2015) Peter J. Houghton et al.   PEDIATRIC BLOOD & CANCER

Preclinical evaluation of nanoparticle albumin-bound paclitaxel for treatment of pediatric bone sarcoma

(2014) Lars M. Wagner et al.   PEDIATRIC BLOOD & CANCER

Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: A report from the children's oncology group

(2014) Lars M. Wagner et al.   PEDIATRIC BLOOD & CANCER

SPARC Expression Correlates with Tumor Response to Albumin-Bound Paclitaxel in Head and Neck Cancer Patients

(2014) Neil Desai et al.   Translational Oncology

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

(2013) Daniel D. Von Hoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase II Trial of Nab-Paclitaxel Compared With Docetaxel as First-Line Chemotherapy in Patients With Metastatic Breast Cancer: Final Analysis of Overall Survival

(2012) William J. Gradishar et al.   Clinical Breast Cancer

Phase II Study of Sequential Gemcitabine Followed by Docetaxel for Recurrent Ewing Sarcoma, Osteosarcoma, or Unresectable or Locally Recurrent Chondrosarcoma: Results of Sarcoma Alliance for Research Through Collaboration Study 003

(2012) E. Fox et al.   ONCOLOGIST

Gemcitabine and docetaxel (GEMDOX) for the treatment of relapsed and refractory pediatric sarcomas

(2012) Louis Rapkin et al.   PEDIATRIC BLOOD & CANCER

Treatment of Ewing sarcoma family of tumors with a modified P6 protocol in children and adolescents

(2011) Jaume Mora et al.   PEDIATRIC BLOOD & CANCER

Update on gemcitabine and docetaxel combination therapy for primary and metastatic sarcomas

(2010) Martee L Hensley   CURRENT OPINION IN ONCOLOGY

Treatment of Relapsed/Refractory Pediatric Sarcomas With Gemcitabine and Docetaxel

(2009) Jaume Mora et al.   JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY

Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane(R)) in combination with gemcitabine in patients with metastatic breast cancer (N0531)

(2008) V. Roy et al.   ANNALS OF ONCOLOGY

Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status

(2008) Neil P. Desai et al.   ANTI-CANCER DRUGS

Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma

(2008) Fariba Navid et al.   CANCER

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Prolonged Versus Standard Gemcitabine Infusion: Translation of Molecular Pharmacology to New Treatment Strategy

(2008) S. A. Veltkamp et al.   ONCOLOGIST